Legend Biotech Corporation - American Depositary Shares (LEGN)

Competitors to Legend Biotech Corporation - American Depositary Shares (LEGN)

Bluebird Bio, Inc. 

Bluebird Bio and Legend Biotech are in direct competition in the field of genetic and cell-based therapies. Bluebird focuses on gene therapies, while Legend emphasizes CAR T-cell treatments. Although Bluebird possesses significant scientific advancements and established partnerships, Legend's concentrated focus on enhancing CAR T technology potentially gives it an edge in producing specialized therapies for certain types of cancers.

Bristol Myers Squibb Company 

Bristol Myers Squibb (BMY) and Legend Biotech compete primarily in the field of cell therapy, specifically with BMY's own CAR T-cell therapies and the co-development of therapies involving CAR-T cell technology. BMY has a robust pipeline and greater resources for research and development, giving it a significant market presence. However, Legend Biotech's innovative approach in its flagship product and promising clinical trial results positions it as a noteworthy competitor in this niche market.

Celyad Oncology SA

Celyad Oncology is a smaller player in the CAR T-cell space, competing with Legend Biotech primarily through its unique allogeneic CAR T-cell therapy approach. While Celyad's innovative strategy provides a distinct offering in the market, it generally lacks the same level of financial backing and commercial infrastructure that Legend Biotech possesses, giving Legend a competitive advantage in market penetration and development capabilities.

Gilead Sciences, Inc. 

Gilead Sciences competes with Legend Biotech through its innovation in oncology therapies and cell-based treatments. Gilead's substantial financial resources allow for broader research capabilities and commercialization efforts. While Gilead has an established oncology portfolio, Legend Biotech's ability to partner with larger pharmaceutical companies and its focus on specific therapies could provide it a tactical advantage in niche markets.

Novartis AG 

Novartis and Legend Biotech both focus on advanced therapies for cancer treatment, particularly CAR T-cell therapies. Novartis is known for its early leadership with Kymriah, which puts it in a strong position when compared to Legend Biotech. However, Legend’s specific advancements in the autologous cell therapies market and their unique drug candidate give them a competitive edge in certain therapeutic areas.